GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Shares Outstanding (EOP)

SABS (SAB Biotherapeutics) Shares Outstanding (EOP) : 9.23 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. SAB Biotherapeutics's shares outstanding for the quarter that ended in Sep. 2024 was 9.23 Mil.

SAB Biotherapeutics's quarterly shares outstanding stayed the same from Jun. 2024 (9.23 Mil) to Sep. 2024 (9.23 Mil).

SAB Biotherapeutics's annual shares outstanding increased from Dec. 2022 (5.04 Mil) to Dec. 2023 (9.23 Mil). It means SAB Biotherapeutics issued new shares from Dec. 2022 to Dec. 2023 .


SAB Biotherapeutics Shares Outstanding (EOP) Historical Data

The historical data trend for SAB Biotherapeutics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Shares Outstanding (EOP) Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Shares Outstanding (EOP)
4.35 4.35 4.35 5.04 9.23

SAB Biotherapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.23 9.23 9.23 9.23 9.23

Competitive Comparison of SAB Biotherapeutics's Shares Outstanding (EOP)

For the Biotechnology subindustry, SAB Biotherapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SAB Biotherapeutics's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where SAB Biotherapeutics's Shares Outstanding (EOP) falls into.



SAB Biotherapeutics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


SAB Biotherapeutics  (NAS:SABS) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


SAB Biotherapeutics Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


SAB Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Executives
Eddie Joe Sullivan director, 10 percent owner, officer: Chief Executive Officer 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King officer: CHIEF FINANCIAL OFFICER 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich director, officer: Executive Chairman ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton director, 10 percent owner 225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova officer: Chief Medical Officer RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137

SAB Biotherapeutics Headlines

From GuruFocus

SAb Biotherapeutics Rebrands as SAB BIO

By Marketwired 06-20-2024